Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials
By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore. Read More
|
|
|
DIA 2009 Trendspotting
July 20, 2009 | At last month’s DIA annual meeting in San Diego, I set out in search of the latest trends in the biopharmaceutical industry. To find out what’s happening in the various sectors we cover in eCliniqua, I interviewed myriad attendees, exhibitors, and speakers as I floated around the San Diego Convention Center.
|
|
Lilly: Innovation More Often Involves Drug Delivery Technology
July 6, 2009 | Increasingly, drugs in clinical development incorporate some sort of specialized delivery technology that couples therapeutic benefit with greater ease of use. William Heath, vice president of product research and development at Eli Lilly and Company, talked to eCliniqua about the rise in clinical trial activity around new modes of drug delivery.
|
|
Archimedes Turns Clinical Trial Models into Reality
June 22, 2009 | The Archimedes Model is a mathematical model that simulates human physiology (and the surrounding health care system) by creating virtual trial populations.
|
|
IBM’s Sunny Forecast for Clinical Cloud Computing
June 1, 2009 | “Clinical clouds” may be the only sensible way to access needed software and information as life sciences companies engage in more collaborations, alliances, and partnerships to weather the “perfect storm of unprecedented challenges” bearing down on their collective bottom line, says Paul Papas, IBM Global Business Services.
|
|
GE Plans to Spend $6 Billion on Health-IT
May 8, 2009 | General Electric is set to invest $6 billion over the next six years in health-IT, the company announced yesterday.
|
|
Pharma Sees a Bigger Role for Imaging in Trials
May 4, 2009 | Acquiring medical images is an art form, especially when those images serve as endpoints for clinical trials. So says Kenneth Faulkner, VP of medical imaging for Perceptive Informatics, a subsidiary of PAREXEL.
|
|
Clinical Best Practices Awards Given
May 4, 2009 | Last week at the Bio-IT World Conference & Expo, two clinical Best Practices Awards were given in the Clinical Trial Management and Clinical Trial Design categories.
|
Rethinking Clinical Trials Data Integration There is a gap between the need for data integration and fully integrated systems. To find out why, SAS and Pharmaceutical Executive conducted confidential telephone interviews with senior pharmaceutical executives and CROs. This article discusses recommendations on how to achieve optimal clinical data integration, based on those interviews.
eClinical Trial Technologies Revolutionizing Clinical Development Efficiency This Bio-IT World BriefingON report, sponsored by ClearTrial, presents a selection of recent stories from Bio•IT World and sister publication, eCliniqua, that illustrate how new technologies and approaches can have a profound impact on the management and execution of clinical trials.
Remote Data Capture:Acquisition and Analysis See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.
Bio-IT World & CHI
Impact of the 1000 Genomes Project on the Next Wave of Pharmacogenomic Discovery
 Interview with M. Eileen Dolan, Ph.D., Professor, Medicine, University of Chicago and Speaker at Next-Generation Sequencing Data Management, September 27-29, 2010, Providence, RI
The 1000 Genomes Project aims to provide detailed genetic variation data on >1000 genomes from worldwide populations using the next-generation sequencing technologies. Some of the samples utilized for the 1000 Genomes Project are the International Hap-Map samples that are composed of lymphoblastoid cell lines (LCLs) derived from individuals of different world populations. The detailed map of human genetic variation promised by the 1000 Genomes project will allow a more in-depth analysis of the contribution of genetic variation to drug response. Future studies utilizing this new resource can greatly enhance our understanding of the genetic basis of drug response and other complex traits.
Download Now
More Podcasts
Software Engineer – Computational Biology Center
Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.
Apply: www.mskcciscareers.org. Equal opportunity and affirmative action employer.
|
|
|